Business
Xenon Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate Update
XEN496 Phase 3 Protocol Submitted to FDA and Trial Initiation Anticipated in 2020 Conference Call at 4:30 pm ET Today BURNABY, British Columbia, Aug. 06, 2020
About this update from Xenon Pharmaceuticals Inc.
[{"type":"text","content":"XEN496 Phase 3 Protocol Submitted to FDA and Trial Initiation Anticipated in 2020\n Conference Call at 4:30 pm ET Today BURNABY, British Columbia, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today reported its financial results for second quarter ended June 30, 2020 and provided a corporate update. Dr. Simon Pimstone, Xenon’s Chief Executive Officer, said, “Xenon continues to manage well as we respond to the global impacts of the COVID-19 pandemic. We are looking forward to a number of key milestone events during the next 12 months, including topline data from our XEN1101 Phase 2b clinical trial, the anticipated start of a Phase 3 clinical trial with XEN496, data from our Phase 2 proof-of-concept trial with XEN007, and the initiation of a Phase 2 trial in our partnered program with Neurocrine.” Dr. Pimstone continued, “We have now filed our XEN496 Phase 3 protocol with the FDA, having implemented the recommendations made by the agency in previous interactions, and we expect feedback in the near-term to support our plans to initiate this trial in KCNQ2-DEE patients this year. We also continue to advance our XEN1101 Phase 2b “X-TOLE” clinical trial currently underway in adult focal epilepsy with topline data expected in the first half of 2021 as previously guided, and we are exploring other potential indications for the novel Kv7 potassium channel modulator. Our collaborator, Neurocrine, anticipates filing an IND in the near-term supporting the initiation of a Phase 2 clinical trial examining NBI-921352 in patients with SCN8A-related epilepsy in the second half of this year.” Dr. Pimstone added, “I am also very pleased to welcome Sheila Grant to our senior leadership team as Xenon’s Senior Vice President, R&D Operations. Sheila has more than 20 years of senior-level experience in the pharmaceutical industry with responsibilities that have encompassed global regulatory, manufacturing and supply chain operations for multiple commercial-stage drugs registered in numerous countries. I am confident Sheila’s expertise will support Xenon’s growth and maturation as we advance our neurology programs into late stage clinical development and increase our focus on commercialization efforts.” Highlights and Anticipated Milestones Proprietary Programs XEN1101 is a di...